NasdaqCM:XBIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Xenetic Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: XBIO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

14.8%

XBIO

3.8%

US Biotechs

2.8%

US Market


1 Year Return

-17.9%

XBIO

24.5%

US Biotechs

20.9%

US Market

Return vs Industry: XBIO underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: XBIO underperformed the US Market which returned 20.9% over the past year.


Shareholder returns

XBIOIndustryMarket
7 Day14.8%3.8%2.8%
30 Day16.9%12.2%11.1%
90 Day-2.9%10.1%6.5%
1 Year-17.9%-17.9%26.6%24.5%23.6%20.9%
3 Year-96.1%-96.1%24.2%17.8%47.3%37.6%
5 Year-99.4%-99.4%13.7%5.9%94.3%72.9%

Long-Term Price Volatility Vs. Market

How volatile is Xenetic Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xenetic Biosciences undervalued compared to its fair value and its price relative to the market?

0.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: XBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XBIO is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Xenetic Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XBIO's revenue (43.2% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: XBIO's revenue (43.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XBIO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xenetic Biosciences performed over the past 5 years?

26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XBIO is currently unprofitable.

Growing Profit Margin: XBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare XBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: XBIO has a negative Return on Equity (-137.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xenetic Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: XBIO's short term assets ($8.0M) exceed its short term liabilities ($788.5K).

Long Term Liabilities: XBIO has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: XBIO is debt free.

Reducing Debt: XBIO has no debt compared to 5 years ago when its debt to equity ratio was 61.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XBIO has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.1% each year.


Next Steps

Dividend

What is Xenetic Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Jeff Eisenberg (54 yo)

3.08yrs

Tenure

US$602,652

Compensation

Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also serves as it...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD602.65K) is about average for companies of similar size in the US market ($USD561.84K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Eisenberg
CEO, President & Director3.08yrsUS$602.65kno data
James Parslow
CFO, COO & Corporate Secretary3.58yrsUS$387.82k0%
$ 0
Curtis Lockshin
Chief Scientific Officer3.83yrsUS$383.79k0%
$ 0

3.6yrs

Average Tenure

55yo

Average Age

Experienced Management: XBIO's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Eisenberg
CEO, President & Director3.08yrsUS$602.65kno data
Adam Logal
Independent Chairman of the Boardno dataUS$80.42k0%
$ 0
Roger Kornberg
Independent Director4.75yrsUS$80.42k0%
$ 0
Firdaus Dastoor
Independent Director6.83yrsUS$80.42k0%
$ 0
James Callaway
Independent Director3.25yrsUS$80.42k0%
$ 0
Dmitry Genkin
Director3.25yrsno data1.49%
$ 94.5k
Alexander Gabibov
Member of Scientific Advisory Board8.17yrsno datano data
Guenther Koehne
Member of Scientific Advisory Board1.5yrsno datano data
Matthew Frigault
Member of Scientific Advisory Board1.83yrsno datano data
Alexey Vinogradov
Independent Director1.33yrsUS$52.09k2.97%
$ 188.6k
Grigory Borisenko
Independent Non-Executive Director1.17yrsno datano data
Maksim Mamonkin
Member of Scientific Advisory Board0.75yrno datano data

3.3yrs

Average Tenure

54yo

Average Age

Experienced Board: XBIO's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Company Information

Xenetic Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xenetic Biosciences, Inc.
  • Ticker: XBIO
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.359m
  • Shares outstanding: 6.30m
  • Website: https://www.xeneticbio.com

Number of Employees


Location

  • Xenetic Biosciences, Inc.
  • 40 Speen Street
  • Suite 102
  • Framingham
  • Massachusetts
  • 1701
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XBIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2014

Biography

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor n...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 23:55
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.